The U.S., China, and Russia are in a "vaccine race" that treats a global challenge like a winner-take-all game.
All for one (vaccine)<p>Launched this April, <a href="https://www.who.int/initiatives/act-accelerator" target="_blank">the Access to COVID-19 Tools (ACT) Accelerator</a> brought together a panoply of governments, scientists, businesses, and global health organizations with the goal of accelerating the development, production, and distribution of an efficacious COVID-19 vaccine. The "vaccines pillar" of this initiative is <a href="https://www.gavi.org/vaccineswork/covax-explained" target="_blank">the COVAX Facility</a>.</p><p>COVAX is coordinated by the WHO, the Coalition for Epidemic Preparedness Innovations (CEPI), and Gavi, the Vaccine Alliance. The program maintains a diverse portfolio of COVID-10 vaccines, monitoring each to identify promising candidates. It has also partnered with manufacturers to ease investment risks and serves as a purchasing pool for self-financing countries, while offering fundraising efforts to poorer ones.</p><p>"[G]overnments from every continent have chosen to work together, not only to secure vaccines for their own populations, but also to help ensure that vaccines are available to the most vulnerable everywhere," Seth Berkley, CEO of Gavi, <a href="https://www.gavi.org/news/media-room/boost-global-response-covid-19-economies-worldwide-formally-sign-covax-facility" target="_blank">said in a release</a>. "With the commitments we're announcing today for the COVAX Facility, as well as the historic partnership we are forging with industry, we now stand a far better chance of ending the acute phase of this pandemic once safe, effective vaccines become available."</p><p><a href="https://www.vox.com/21448719/covid-19-vaccine-covax-who-gavi-cepi" target="_blank" rel="noopener noreferrer">In an interview with Vox</a>, Berkley noted that the ACT Accelerator is the largest global collaboration since the Paris Climate Agreement. He added, "This type of solidarity is critical because otherwise what you're going to end up with is just a constant reintroduction of infections and the inability to go back to normal."</p><p>As of Monday, 64 higher-income countries and 92 low- and middle-income countries—representing nearly two-thirds of the world's population—<a href="https://www.gavi.org/news/media-room/boost-global-response-covid-19-economies-worldwide-formally-sign-covax-facility" target="_blank" rel="noopener noreferrer">have signed commitments to COVAX</a>. Thirty-eight more are expected to sign soon.</p><p>COVAX's goal is to have 2 billion doses by the end of 2021. Experts estimate this amount will cover high-risk and vulnerable people, as well as healthcare workers, worldwide. Participating nations must cover those populations before administering vaccines according to national priorities. As part of the agreement, countries agree to support equal access to the vaccine once it becomes available, a move aimed at preventing hoarding and price gouging. </p><p>Currently, CEPI is supporting nine candidate vaccines, of which eight are in clinical trials.</p>
Why has the U.S. backed out?<span style="display:block;position:relative;padding-top:56.25%;" class="rm-shortcode" data-rm-shortcode-id="7167e0bf1593a7cb29c1a116041116e3"><iframe type="lazy-iframe" data-runner-src="https://www.youtube.com/embed/LUAsKbH7yeY?rel=0" width="100%" height="auto" frameborder="0" scrolling="no" style="position:absolute;top:0;left:0;width:100%;height:100%;"></iframe></span><p>The United States is gambling that its bilateral deals with various pharmaceutical companies will win the "<a href="https://www.washingtonpost.com/world/coronavirus-vaccine-trump/2020/09/01/b44b42be-e965-11ea-bf44-0d31c85838a5_story.html" target="_blank" rel="noopener noreferrer">vaccine race</a>." This U.S.-only initiative, named (sigh) <a href="https://www.hhs.gov/about/news/2020/06/16/fact-sheet-explaining-operation-warp-speed.html" target="_blank" rel="noopener noreferrer">Operation Warp Speed</a>, has already spent <a href="https://www.cnbc.com/2020/08/14/the-us-has-already-invested-billions-on-potential-coronavirus-vaccines-heres-where-the-deals-stand.html" target="_blank" rel="noopener noreferrer">approximately $10 billion</a> and is pushing to deliver 300 million doses by January 2021. Many experts worry this speedy push through the regulatory path could result in <a href="https://www.sciencemag.org/news/2020/08/here-s-how-us-could-release-covid-19-vaccine-election-and-why-scares-some" target="_blank" rel="noopener noreferrer">premature and dangerous approvals</a>.</p><p>China and Russia have likewise bet on their own high-priced ponies. Russia is touting <a href="https://arstechnica.com/science/2020/09/russia-offers-its-untested-covid-19-vaccine-for-free-to-un-officials/" target="_blank" rel="noopener noreferrer">an unvetted vaccine</a> nicknamed (double sigh) "Sputnik V." This vaccine has only concluded <a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30402-1/fulltext" target="_blank" rel="noopener noreferrer">phase 1 and 2 trials</a> with a small number of participants, yet Russia claims to have already received international requests. Meanwhile, China has administered <a href="https://www.reuters.com/article/us-health-coronavirus-china-vaccines-foc/in-coronavirus-vaccine-race-china-inoculates-thousands-before-trials-are-completed-idUSKBN26705Q" target="_blank" rel="noopener noreferrer">tens of thousands of doses of a vaccine</a> before completing phase 3 clinical trials. </p><p>An additional barrier to the United States' participation: COVAX is a WHO-led initiative. Earlier this year, <a href="https://www.npr.org/2020/05/29/865685798/president-trump-announces-that-u-s-will-leave-who" target="_blank" rel="noopener noreferrer">President Donald Trump admonished the WHO as a corrupt organization</a> and claimed it assisted China in covering up the coronavirus outbreak and its severity. Though he presented no evidence for the accusation, Trump has used it as the basis for <a href="https://www.statnews.com/2020/09/21/64-high-income-nations-join-effort-to-expand-global-access-to-covid-19-vaccines-but-u-s-and-china-do-not/" target="_blank" rel="noopener noreferrer">his threat to cut ties with</a>, and funding for, the agency.</p><p>"The United States will continue to engage our international partners to ensure we defeat this virus, but we will not be constrained by multilateral organizations influenced by the corrupt World Health Organization and China," said Judd Deere, a spokesman for the White House, said <a href="https://www.reuters.com/article/us-health-coronavirus-usa-who/white-house-slams-who-over-criticism-of-push-for-covid-19-vaccine-idUSKBN25S62T" target="_blank" rel="noopener noreferrer">in a statement</a>.</p><p>He added, "This president will spare no expense to ensure that any new vaccine maintains our own FDA's gold standard for safety and efficacy, is thoroughly tested, and saves lives."</p><p>By shirking COVAX, these countries hope to gain peerless access to a vaccine. Each could secure large numbers of doses for its citizens while also reaping the political boons to follow. In the United States, President Trump has pinned his re-election bid on a timely vaccine, while Chinese officials seem posed to use a vaccine <a href="https://www.nytimes.com/2020/09/11/business/china-vaccine-diplomacy.html" target="_blank" rel="noopener noreferrer">to repair diplomatic ties</a>. </p><p>But the loss of such rich economies will prove a blow to COVAX and the ACT Accelerator. Vaccines are notoriously expensive and risky to develop; the costs to manufacture doses at scale will be immense. <a href="https://news.un.org/en/story/2020/08/1070162" target="_blank" rel="noopener noreferrer">WHO Director-General Tedros Adhanom Ghebreyesus</a> stated the ACT Accelerator would cost roughly $30 billion, and the final bill for the tools to combat novel coronavirus would be at least $100 billion. But that's a pittance compared to the <a href="https://www.reuters.com/article/us-health-coronavirus-imf/imf-says-10-trillion-spent-to-combat-pandemic-far-more-needed-idUSKBN23I27P" target="_blank" rel="noopener noreferrer">$10 trillion already spent on the pandemic</a> so far.</p><p>"COVID-19 is an unprecedented global crisis that demands an unprecedented global response," <a href="https://www.who.int/news-room/detail/21-09-2020-boost-for-global-response-to-covid-19-as-economies-worldwide-formally-sign-up-to-covax-facility" target="_blank" rel="noopener noreferrer">Tedros said</a>. "Vaccine nationalism will only perpetuate the disease and prolong the global recovery. Working together through the COVAX Facility is not charity, it's in every country's own best interests to control the pandemic and accelerate the global economic recovery."</p>
The winner won't necessarily take all<img type="lazy-image" data-runner-src="https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNDQzNzY2My9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTY0NjExMzA1M30.2kF2U_8veNWxmaxOnSned_WTQMRtscbB5dmT5efJHsc/img.jpg?width=1245&coordinates=0%2C180%2C0%2C181&height=700" id="55cd7" class="rm-shortcode" data-rm-shortcode-id="c56717cda300a40edc23795c8ee23c2f" data-rm-shortcode-name="rebelmouse-image" alt="SARS-CoV-2 vaccine" />
New research conducted on mice suggests repeated heavy drinking causes synaptic dysfunctions that lead to anxiety.
- The study was conducted on mice, who were given the equivalent of five drinks daily for 10 days.
- Images of the alcoholic mice brains showed synaptic dysfunctions related to microglia (immune cells in the brain).
- The results suggest that regulating TNF, a signaling protein related to systemic inflammation, may someday play a part in treating alcohol addiction.
3D surface rendering of confocal maximum projection images showing volume reconstruction of PSD-95 within CD68 structures in microglia (Iba1+ cell) on tissue sections from prefrontal cortices of WT and TNF KO mice after exposure to EtOH or H2O
The role of TNF in anxiety<p>But the new study revealed an interesting finding about TNF. To find out how TNF interacts with anxiety, the researchers gave to the alcoholic mice a drug called <a href="https://www.drugs.com/mtm/pomalidomide.html" target="_blank">pomalidomide</a>, which blocks the production of TNF. After, the mice showed improved synaptic functioning and less anxiety-like behaviors.</p><p style="margin-left: 20px;">"This study suggests that regulating the levels of TNF might eventually be useful when treating alcohol addiction," Relvas told Inverse.</p>
Pixabay<p>Still, it's unclear whether or how TNF regulation might work its way into alcohol addiction treatments. After all, even if science can fix the anxiety aspect of alcoholism, heavy drinking still exacts heavy tolls on other parts of the body and brain.</p><p>For now, it's probably best to keep your drinking within moderate levels: <a href="https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/guidelines/appendix-9/" target="_blank">Most</a> <a href="https://www.nytimes.com/2018/08/27/health/alcohol-drinking-health.html" target="_blank">research</a> suggests that having one to two drinks per day yields no significant negative health consequences.</p>
UNC School of Medicine researchers identified the amino acid responsible for the trip.
- Researchers at UNC's School of Medicine have discovered the protein responsible for LSD's psychedelic effects.
- A single amino acid—part of the protein, Gαq—activates the mind-bending experience.
- The researchers hope this identification helps shape depression treatment.
What is Bicycle Day?<span style="display:block;position:relative;padding-top:56.25%;" class="rm-shortcode" data-rm-shortcode-id="d346092205da3c9ed10bad283222c9f1"><iframe type="lazy-iframe" data-runner-src="https://www.youtube.com/embed/L32mAiLXnLs?rel=0" width="100%" height="auto" frameborder="0" scrolling="no" style="position:absolute;top:0;left:0;width:100%;height:100%;"></iframe></span><p>Back in the world of clinical science, LSD has always showed promise. That trend continues as restrictions are finally easing up. Understanding LSD's effects on our brain's complex system of networks is an important step toward discovering therapeutic actions. As Roth <a href="https://www.inverse.com/mind-body/how-lsd-binds-to-the-brain-study" target="_blank">says</a> of his research,</p><p style="margin-left: 20px;">"Now we know how psychedelic drugs work – finally! Now we can use this information to, hopefully, discover better medications for many psychiatric diseases."</p><p>Using X-ray crystallography, Roth's team discovered a single amino acid—a building block of the protein, Gαq—responsible for binding to serotonin receptors. As LSD is only a partial agonist, they also experimented with a full-agonist designer psychedelic in order to observe complete receptor activation. This amino acid appears to be the master switch for the psychedelic experience. </p><p>While psilocybin has been in the news, the psychedelic renaissance is expanding in all directions. Phase 1 clinical trials on the <a href="https://newatlas.com/science/landmark-clinical-trial-lsd-mdma-mindmed/" target="_blank">combination</a> of LSD, MDMA, and psychotherapy will soon commence. LSD's effects on <a href="https://clinicaltrials.gov/ct2/show/NCT03866252" target="_blank" rel="noopener noreferrer">Major Depressive Disorder</a> and <a href="https://www.sciencealert.com/first-clinical-trial-shows-micro-doses-of-lsd-can-increase-a-person-s-pain-tolerance" target="_blank">pain management</a> are ongoing. With the <a href="https://www.bloomberg.com/news/articles/2020-09-18/-magic-mushroom-company-moves-toward-mainstream-in-nasdaq-ipo" target="_blank" rel="noopener noreferrer">first psychedelics company</a> to IPO on the American stock market, along with hundreds of millions of dollars of investment flowing into similar companies and organizations, the push for legalized psychedelics intensifies. </p>
Credit: ynsga / Shutterstock<p>Researchers are actively attempting to remove the hallucinogenic component of psychedelics for widespread therapeutic usage—<a href="https://www.healtheuropa.eu/could-ibogaine-offer-a-revolutionary-long-term-solution-to-addiction/100635/" target="_blank">trials</a> using ibogaine for addiction treatment, for example. Identifying the chemical effects of psychedelics on our brains is an essential step in that process.</p><p>Of course, believing psychedelics <em>only</em> matters to brain chemistry is problematic as well. The rituals associated with their use are just as relevant. The "<a href="https://en.wikipedia.org/wiki/Set_and_setting" target="_blank">set and setting</a>" model espoused by Timothy Leary reminds us that biology isn't everything; environmental factors play just as important a role in mental health. </p><p>Isolating specific chemicals without understanding the impact of the drug <em>and</em> the environment overlooks the holistic nature of the psychedelic experience. For example, ketamine trials <a href="https://bigthink.com/surprising-science/ketamine-depression" target="_self">were rushed</a> and could potentially backfire; we can't afford to make that mistake again. </p><p>Still, understanding the pathways LSD utilizes is an important step forward. As Roth says, "Our ultimate goal is to see if we can discover medications which are effective, like psilocybin, for depression but do not have the intense psychedelic actions." In a world where more people are growing anxious and depressed by the day, every intervention should be explored.</p><p> --</p><p><em>Stay in touch with Derek on <a href="http://www.twitter.com/derekberes" target="_blank">Twitter</a>, <a href="https://www.facebook.com/DerekBeresdotcom" target="_blank" rel="noopener noreferrer">Facebook</a> and <a href="https://derekberes.substack.com/" target="_blank" rel="noopener noreferrer">Substack</a>. His next book is</em> "<em>Hero's Dose: The Case For Psychedelics in Ritual and Therapy."</em></p>
Research from Ohio State finds that acetaminophen affects our emotions.
- Previous research has shown that acetaminophen dulls both our positive and negative feelings.
- The new study finds that those taking the drug consider risks they've been presented as less scary.
- Acetaminophen is an important everyday painkiller, so it's a good idea to factor in what it may be doing to our judgement.
Walking alone in a scary part of town<img type="lazy-image" data-runner-src="https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNDIzNjMzMy9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTY0NDc0OTY5OX0.UZiwCiNAST22Zm-FSuhRgQlPAEQh57v7V-6N6dzctqc/img.jpg?width=980" id="c673a" class="rm-shortcode" data-rm-shortcode-id="e4393f1a54fad097172ee9e92a18d3da" data-rm-shortcode-name="rebelmouse-image" alt="person standing on bridge at night" />
Credit: Francois Hoang/Unsplash<p>As part of the study, individuals rated the degree of risk they perceived in a range of activities such as "bungee jumping off a tall bridge" and "speaking your mind about an unpopular issue in a meeting at work." They considered these activities to be less risky than a control group not taking the medication.</p><p>In the first of the study's experiments, 189 college students took either 1,000 mg of acetaminophen — the standard dosage for headache pain — or a similar-looking placebo.</p><p>After giving the acetaminophen time to take effect, those in the study ranked the level of risk they perceived to be associated with a series of activities, on a scale of 1 to 7. Among the activities were walking alone in an unsafe area after dark, bungee jumping, changing careers in one's 30s, and taking a skydiving class. The students taking acetaminophen considered these activities less risky than the control group.</p><p>An additional three studies in which individuals participated in an <a href="http://www.impulsivity.org/measurement/BART" target="_blank">online risk game</a> confirmed this result. In this game, you click to pump up a virtual balloon — as the balloon gets bigger, you earn more money. If the balloon pops, you lose your earnings.</p><p>The acetaminophen-takers proved to be bolder than their control counterparts. People in the control group pumped less and successfully cashed out more often. Recalls Dr. Way, "for those who are on acetaminophen, as the balloon gets bigger, we believe they have less anxiety and less negative emotion about how big the balloon is getting and the possibility of it bursting." They pumped more times, and indeed popped more balloons.</p>
Takeaway<p>Acetaminophen is an important weapon in the modern medical arsenal. Dr. Way points out that it's the CDC's <a href="https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html" target="_blank">recommended go-to drug</a> for COVID-19 symptoms. In addition to calming our pounding noggins, surgeons typically prescribe acetaminophen, often with codeine, for post-surgical pain relief; your dentists may also suggest it. Its value lies in how well it works, and also that it's more gentle on our digestive systems than some other painkillers such as <a href="https://en.wikipedia.org/wiki/Nonsteroidal_anti-inflammatory_drug" target="_blank">NSAIDs</a>, drugs that contain <a href="https://en.wikipedia.org/wiki/Ibuprofen" target="_blank">ibuprofen</a>. NSAIDs taken regularly pose danger to one's digestive tract.</p><p>Given that we're unlikely to stop taking acetaminophen for our aches and pains, the study represents a helpful little wakeup call. Perhaps we should pump the brakes a bit as we consider risks when we're taking acetaminophen. Take a beat, think twice, and only then carefully secure that bungee cord before you leap.</p>
Novichok means "newcomer" in Russian.